Abstract
Bones are the third most common sites for cancer metastasis after lung and liver. Bone metastasis cause skeletal complications (SRE’s) that affect the quality of life of patients with bone metastasis. Management of these patients depend on the primary tumor and pattern of bone metastasis.
The aim of this study was to describe the origin, distribution pattern of bone metastases, common SRE’s and proportion of patients with bone metastasis that need surgery.
A cross sectional study was conducted among cancer patients with Metastatic bone disease attending KCMC Hospital from November 2022 to April 2023. Data was collected from patient’s files, histopathology and radiology reports by a structured extraction sheet. VAS, SINS and Mirel’s scores was used to document pain severity, spinal instability and fracture risk respectively. The ASIA impairment scale was used for documenting neurological deficits in patients with spine metastasis. Data was entered and analyzed in SPSS version 25.0
A total of 72 participants were enrolled. Their mean age was 69 ± 11 years and (75%) were male. Prostate cancer (65.3%) was the leading cause of metastatic bone disease followed by breast cancer (18.1%). Most of patients with MBD have multiple lesions (91.7%) involving multiple sites but the spine (93.1%) was the mostly affected site. Osteoblastic lesions were the predominant radiological type by 59.7% followed by osteolytic lesions which accounted for 23.6% of the study participants. 30.6% had pathological fractures and half of these occurred in patients with osteolytics lesions. 36.1% of the study participants had an indication for surgical treatment of the bone metastasis.
Most of MBD originate from Prostate and Breast cancer giving multiple lesions involving multiple sites but the spine remains to be the most affected site. Even though about a third of the patients had SRE’s that needed surgical intervention but few are expected to be operated considering the prognosis. This calls for more emphasis on prevention of SRE’s and use of appropriate less invasive therapies to prevent progression of the disease.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No financial assistance receivedno
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Approval to conduct the research was obtained from the Kilimanjaro Christian Medical University College Research, Ethics and Review Committee (CRERC) with clearance number PG94/2022.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All the data is available at the Cancer Care center registry of the Kilimanjaro Christian Medical center Hospital. This data cannot be accessed online for patient's privacy and ethical reasons
